Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis

Jie Liu,Huaying Fang,Na Hong,Chaolan Lv,Qihua Zhu,Yinping Feng,Bo Wang,Jiashuang Tian,Yue Yu
DOI: https://doi.org/10.1128/spectrum.01457-23
IF: 3.7
2023-05-18
Microbiology Spectrum
Abstract:It is reported that patients with ulcerative colitis (UC) have low response rates to anti-integrin medications in the latest VARSITY study. Therefore, our primary goals were to discover differences in the gut microbiome and metabonomics patterns between early remission and nonremission patients and to explore the diagnostic value in predicting clinical remission to anti-integrin therapy accurately.
microbiology
What problem does this paper attempt to address?